A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)

Lung Cancer

Volumn 56, Issue 2, 2007, Pages 247-254

  Schallier, D ^a   Neyns, B ^a   Fontaine, C ^a   Steene, J Vande ^a   De Mey, J ^a   Meysman, M ^a   De Greve J ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Induction chemotherapy; Locally advanced (stage III); NSCLC; Radiotherapy

Indexed keywords

ALIZAPRIDE; ANTIBIOTIC AGENT; CARBOPLATIN; DEXAMETHASONE; GEMCITABINE; ONDANSETRON; PACLITAXEL; PROMETHAZINE; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GASTROENTERITIS; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; SURVIVAL RATE;

EID: 34247101492     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.12.017     Document Type: Article

References (28)

1. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
2. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetiyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide and cisplatin in unresectable non small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
3. Ellis P.A., Smith I.E., Hardy J.R., Nicolson M.C., Talbot D.C., Ashley S.E., et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71 (1995) 366-370
4. Hickish T.F., Smith I.E., O'Brien M.E.R., Ashley S., and Middleton G. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 78 (1998) 28-33
5. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, where, why? Supplement to JCO 2002; vol. 20: 18: 235-335.
6. Chang A.J., Kim K., Glick J., Anderson T., Karp D., and Johnson D. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85 (1993) 388-394
7. Murphy W.K., Fossella F.W., Winn R.L., Shin D.M., Hynes H.E., Gross H.M., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85 (1993) 384-388
8. Von Pauwel J., Wagner H., Niederle N., Heider A., Koschel G., Hecker D., et al. Phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin Oncol 23 Suppl. 16 (1996) 47-50
9. Bonomi P. Review of paclitaxel-carboplatin in advanced non-small-cell lung cancer. Semin Oncol 26 Suppl. 2 (1999) 55-59
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
11. Kelly K. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol 10 Suppl 5 (1999) 53-56
12. Hainsworth J.D., Burris II H.A., Erland J.B., Morrissey L.H., Meluch A.A., Kalman L.A., et al. Phase I/II trial of paclitaxel by 1 h infusion, carboplatin and gemcitabine in the treatment of patients with advanced non-small-cell lung carcinoma. Cancer 85 (1999) 1269-1276
13. Kelly K., Mikhaeel-Kamel N., Pan Zhaoxing, Murphy J., Prindiville S., and Bunn P.A. A phase I/II trial of paclitaxel, carboplatin and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 6 (2000) 3474-3479
14. Favaretto A., Ceresoli G.L., Paccagnella A., Barbieri F., Bearz A., Ghiotto C., et al. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Ann Oncol 11 (2000) 1421-1426
15. Paccagnella A., Oniga F., Bearz A., Favaretto A., Clerici M., Barbieri F., et al. Adding gemcitabine to paclitaxel/carboplatin increases survival in advanced non small cell lung cancer: results of a phase II-III study. J Clin Oncol 24 (2006) 681-687
16. Spira A., and Ettinger D. Multidisciplinary management of lung cancer. NEJM 350 14 (2004) 379-392
17. Furuse K., Fukuoka M., Kawakara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
18. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc ASCO 22 (2003) 621A
19. Belani P.C., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non small-cell lung cancer: a randomised phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
20. Fournel P., Robinet G., Thomas P., Souquet P.J., Lena H., Vergnenegre A., et al. Randomised phase III trial of sequential chemoradiotherapy compared with concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint Etienne d'Oncologie Thoracique- Groupe Français de Pneumo-Cancerologie NPC 95.1 study. J Clin Oncol (2005) 5910-5917
21. Zatloukal P.V., Peruzelka I., Zemenova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential radio chemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small-cell lung cancer: a randomised phase II study. Lung Cancer 46 1 (2004) 87-98
22. Huber R.M., Flentje M., Schmidt M., Pöllinger, Gosse H., Willner J., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non small-cell lung cancer: study CTRT 99/97 by the bronchial carcinoma therapy group. J Clin Oncol 24 (2006) 4397-4404
23. World Health Organisation. A handbook for reporting results of cancer treatment: World Health Organisation 38 (1979), WHO Publication, Geneva, Switzerland
24. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 53 (1986) 487-581
25. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 487-581
26. Cox D.R. Regression models and life tables. JR Stat Soc (B) 34 (1972) 187-220
27. Everaert H., Schallier D., Neyns B., Baelde N., Meysman M., and De Grève J. Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non-small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S). Proc Soc Nuclear Med 2006 (1747)
28. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80